ALKFusion

ALKFusion is a precision oncology biotechnology company focused on developing next-generation therapies for patients with ALK-rearranged cancers, such as ALK-positive non-small cell lung cancer (NSCLC). Founded by leading experts from the University of Colorado, the company leverages deep expertise in ALK biology and resistance mechanisms to design novel small molecule inhibitors. Their primary objective is to overcome the limitations of current tyrosine kinase inhibitors (TKIs), specifically targeting acquired resistance mutations that lead to treatment failure. ALKFusion aims to provide more durable and effective treatment options for patients whose cancers have evolved beyond existing standard-of-care therapies. The company is currently in the pre-clinical stage, advancing its lead candidates toward potential clinical evaluation.